This article is more than 5 years old. Information may no longer be current.

EGFR806 CAR T-cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Issue: December 2018 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase I, open-label, non-randomized study enrolling pediatric and young adults with relapsed or refractory non-CNS solid tumors to evaluate safety, feasibility, and efficacy of administering T-cell products manufactured from the participant’s blood and genetically modified to express an EGFR-specific receptor to target and kill solid tumors expressing EGFR and the selection-suicide marker EGFRt.